Xiaofang Zhang

Xiaofang Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
RWRuxin Wang
Ruxin Wang
HYHaowen Ye
Haowen Ye
YZYongting Zhao
Yongting Zhao
JWJinjing Wei
Jinjing Wei
YWYing Wang
Ying Wang
LWLihong Wang
Lihong Wang
Background: Sacubitril/valsartan and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) therapies were reported to affect glycaemic control and the development of diabetes mellitus (DM), but the findings are inconsistent. We examined the evidence for the effects of sacubitril/valsartan and ACEI/ARB in DM by conducting a meta-analysis. Methods: The Cochrane Central Register of Controlled Trials (The Cochrane Library), Embase, PubMed, and ClinicalTrials.gov were searched for data from randomised clinical trials (RCTs) that evaluated the efficacy of sacubitril/valsartan and ACEI/ARB in patients, as of May 25, 2022. Patients were grouped by their disease background at baseline. The main outcomes were the number of new-onset DM and hypoglycaemia, elevated glycaemia, inadequate DM control, diabetes treatment, and diabetic complications, from baseline to the end of the trials. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (ROB 2). The quality of the evidence was evaluated according to the Recommendations for Assessment, Development, and Evaluation guidelines. The meta-analysis of the incidence of various outcomes was conducted using fixed or random effects models. The results are expressed as binary risk, 95% confidence interval (CI), and relative risk (RR). The Mantel-Haenszel method and Z test were used to determine the overall results and determine the significance of the RR. Results: This study included 31 RCTs and 86,809 subjects. Compared with placebo, sacubitril/valsartan treatment significantly reduced the risk of new-onset DM among all patients (RR = 0.78, 95% CI: 0.64–0.95), patients with heart failure (HF) (RR = 0.24, 95% CI: 0.12–0.48), HF with reduced ejection fraction (HFrEF) (RR = 0.24, 95% CI: 0.12–0.50), and HF with preserved ejection fraction (HFpEF) (RR = 0.54, 95% CI 0.34–0.85). In contrast, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among all patients (RR = 1.91, 95% CI: 1.05–3.47), patients with not all-DM (defined as part of the study population having DM at baseline) (RR = 5.71, 95% CI: 2.02–16.21), and patients with HFpEF (RR = 7.06, 95% CI: 2.10–23.76). Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12–3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51–8.55, p = 0.004). Compared with placebo, ACEI/ARB treatment did significantly reduce the risk of new-onset DM among all patients (RR 0.85, 95% CI 0.77–0.93, p = 0.0007) and patients with not all-HF (defined as part of the study population having HF at baseline) (RR 0.87, 95% CI 0.82–0.93, p<0.0001) and HFpEF (RR 0.60, 95% CI 0.44–0.83, p = 0.002), diabetes complications among patients with non-HF (/not all-DM) (RR 0.87, 95% CI 0.76–0.99, p = 0.04), and subsequent diabetes treatment among patients with new-onset DM (RR 0.70, 95% CI 0.58–0.84, p = 0.0002) and significantly increased the risk of hypoglycaemia among patients with not all-DM (RR 2.06, 95% CI 1.172–3.61, p = 0.01). Conclusions: The results of our study, especially in reducing glycaemia and new-onset DM, revealed that sacubitril/valsartan had a positive effect on the control of glycaemia and the development of DM. ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan. The above effects varied across diseases but the evidence was strongest in patients with HF. Trial registration: CRD42022336311.

27 November 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
JWJiaxin Wang
Jiaxin Wang
XLXinyi Lu
Xinyi Lu
YZYongting Zhao
Yongting Zhao
ZJZewei Jiang
Zewei Jiang
JWJinghao Wang
Jinghao Wang
XZXiaofang Zhang
Xiaofang Zhang
Emerging evidence highlights the gut microbiome's role in hypertension via microbial metabolites and endothelial dysfunction, while the Dietary Index for Gut Microbiota (DI‐GM) quantifies diet quality for microbiota health. In addition, leisure‐time physical activity (LTPA) also reduces blood pressure, but their combined impact on population‐level hypertension remains unclear. Therefore, this study explores the individual and joint effects of DI‐GM and LTPA on hypertension risk. To address this objective, we conducted a cross‐sectional study analysis of data from 27,643 adults in the National Health and Nutrition Examination Survey (NHANES 2007–2020). Excluding individuals with incomplete data, key variables included the DI‐GM and LTPA pattern (categorized by intensity, frequency, and regularity; regularly active defined as > 2 days/week). Weighted logistic regression models and restricted cubic splines (RCS) evaluated independent, joint, and non‐linear associations of DI‐GM and LTPA with hypertension, adjusting for covariates. The results showed that higher DI‐GM scores and greater weekly LTPA were inversely correlated with hypertension risk, exhibiting dose‐dependent patterns (16% lower odds for DI‐GM ≥ 6 vs. lowest groups; 16%–24% lower odds for LTPA (≥ 150 min/week) vs. lowest groups). RCS analysis showed a linear inverse dose–response relationship between DI‐GM and hypertension. The regularly active LTPA pattern (> 2 days/week) was linked to a 24% lower risk of hypertension (OR = 0.76, 95% CI = 0.69–0.84), and there was also a significant association observed for the weekend warrior LTPA pattern (1–2 days/week) (OR = 0.80, 95% CI = 0.64–0.99). Notably, joint analysis demonstrated that individuals with DI‐GM > 4 scores and LTPA ≥ 150 min/week or regularly LTPA pattern exhibited the lowest hypertension odds. In conclusion, both a high DI‐GM score (≥ 6 points) and sufficient LTPA (≥ 150 min/week) were independently associated with reduced odds of hypertension, with their combined effect amplifying protective benefits. Prospective studies are warranted to confirm temporality and causal pathways.

10 November 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
RWRuxin Wang
Ruxin Wang
HYHaowen Ye
Haowen Ye
YWYing Wang
Ying Wang
LMLi Ma
Li Ma
JWJinjing Wei
Jinjing Wei
LWLihong Wang
Lihong Wang
Radiation therapy (RT) is one of the common and widely used treatment method for thyroid tumors. Considering that the thyroid is located close to the heart, the radiation generated during the treatment of thyroid tumors may have an adverse greater impact on the heart. This study is to explore the influencing factors, especially additional effects of RT, on cardiac-specific death among patients with malignant thyroid tumors. Collecting information from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database using SEER*Stat. Patients with malignant thyroid tumors were searched, whether receiving RT or not. Ultimately, 201, 346 eligible patients were included. Propensity Score Matching (PSM) was used to minimize bias of baseline characteristics by adjusting for confounding factors. COX (proportional hazards) and fine-gray (competing risk) model regression analysis were used to explore the effects of various influencing factors on cardiac-specific death. The present analysis showed that, compared with non-RT, RT based upon radioactive implants and beam radiation were associated with lower risk of cardiac-specific death in patients with thyroid malignancy, beam radiation therapy may had a similar effect. Besides, the remaining RT methods did not significantly increase the risk of cardiac-specific death. In addition, Asian or Pacific Islander ethnicity, female sex, marital status, combined summary stage (localized, regional, and distant), high-income, and later year of diagnosis were associated with lower risk of cardiac-specific death. While older age of diagnosis, African ethnicity, non-Hispanic ancestry, and derived AJCC stage (IV) were risk factors for cardiac-specific death. These results help to identify the factors influencing cardiac-specific death among patients with thyroid malignancies. Furthermore, it may helps to improve the clinical application of RT without too much concern about adverse cardiac effects.